Ajinomoto has signed a definitive agreement for the acquisition of contract development and manufacturing organisation and clinical-stage therapeutics company Forge Biologics in an all-cash transaction totalling $620m. The prospective takeover is part of Ajinomoto’s strategy to bolster its global expertise…

Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of all of outstanding shares of Mirati Therapeutics in a $5.8bn deal. The company plans to buy Mirati for $58 for each share in cash, representing an equity…